SignatureDx Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 19

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 3

SignatureDx General Information

Description

Operator of a bioanalytical platform intended to detect and monitor silently progressing complex human diseases. The company specializes in novel methods of prediction and treatment of human disease through non-invasive diagnostic testing, enabling individuals to reduce organ diseases and get successful treatment.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1501 Preble Avenue
  • Suite 200
  • Pittsburgh, PA 15233
  • United States
+1 (412)
Primary Industry
Other Pharmaceuticals and Biotechnology
Vertical(s)
Corporate Office
  • 1501 Preble Avenue
  • Suite 200
  • Pittsburgh, PA 15233
  • United States
+1 (412)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SignatureDx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC 23-Jun-2025 Completed Clinical Trials - General
1. Seed Round 01-Apr-2024 Completed Clinical Trials - General
To view SignatureDx’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

SignatureDx Patents

SignatureDx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250166736-A1 Relational biomarkers that distinguish diseases and disorders from controls and uses thereof to predict pathophysiological outcomes Pending 20-Nov-2023
US-20250266128-A1 Relational biomarkers that distinguish diseases and disorders from controls and uses thereof to predict pathophysiological outcomes Pending 20-Nov-2023

SignatureDx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SignatureDx Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Life Sciences Greenhouse Investments Venture Capital Minority
Innovation Works Venture Capital Minority
LifeX Ventures Accelerator/Incubator Minority
To view SignatureDx’s complete investors history, request access »

SignatureDx FAQs

  • When was SignatureDx founded?

    SignatureDx was founded in 2020.

  • Where is SignatureDx headquartered?

    SignatureDx is headquartered in Pittsburgh, PA.

  • What is the size of SignatureDx?

    SignatureDx has 19 total employees.

  • What industry is SignatureDx in?

    SignatureDx’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is SignatureDx a private or public company?

    SignatureDx is a Private company.

  • What is SignatureDx’s current revenue?

    The current revenue for SignatureDx is .

  • Who are SignatureDx’s investors?

    Life Sciences Greenhouse Investments, Innovation Works, and LifeX Ventures have invested in SignatureDx.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process